Use Of Il-27-p28 To Antagonize Il-6 Mediated Signaling

Abstract

Provided are methods increasing, or, alternatively, decreasing IL-6 and/or gp130-mediated signaling in mammalian subjects using p28. Methods of preventing and/or treating autoimmune disorders, cancer, transplant rejection, and other IL-6-associated diseases, as well as methods of enhancing an IL-6-mediated immune response, are also described.


Claims
Download PDF
Document Preview
Document History
  • Publication: Feb 16, 2012
  • Application: Dec 2, 2009
    US US 99879909 A
  • Priority: Dec 2, 2009
    US US 99879909 A
  • Priority: Dec 2, 2009
    US US 2009/0006354 W
  • Priority: Dec 2, 2008
    US US 20072708 P

Sign in to the Lens

Feedback